Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

  • ID: 3927192
  • Report
  • 51 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • PharmAbcine, Inc.
  • Sevion Therapeutics, Inc.
  • MORE
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

Summary

‘Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016’, provides in depth analysis on Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted pipeline therapeutics.

The report provides comprehensive information on the Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4)
- The report reviews Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • PharmAbcine, Inc.
  • Sevion Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Overview

Therapeutics Development

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Stage of Development

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Therapy Area

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Indication

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Companies

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Companies Involved in Therapeutics Development

AbbVie Inc

OncoMed Pharmaceuticals, Inc.

PharmAbcine, Inc.

Sevion Therapeutics, Inc.

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Drug Profiles

ABT-165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

demcizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit DLL4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMP-305B83 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMC-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Dormant Projects

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Discontinued Products

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Featured News & Press Releases

Sep 01, 2016: OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer

Jun 05, 2016: OncoMed Presents Phase 1b Data on demcizumab at the 2016 ASCO Annual Meeting

May 18, 2016: AbbVie To Present Data on ABT-165 at ASCO 2016

Apr 21, 2016: OncoMed Announces Clinical Data for Demcizumab to be Presented at the 2016 ASCO Annual Meeting

Apr 20, 2016: OncoMed Presents Demcizumab Mechanism Data at the AACR Annual Meeting 2016

Mar 17, 2016: OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)

Jan 22, 2016: OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium

Nov 09, 2015: OncoMed Presents Data From Anti-DLL4/VEGF Bispecific Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nov 07, 2015: OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting

Nov 04, 2015: OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting

Oct 27, 2015: OncoMed to present preclinical results from OMP-305B83 at the AACR-NCI-EORTC International Conference

Aug 10, 2015: OncoMed Pharmaceuticals Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data

Jun 01, 2015: OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting

Jun 01, 2015: OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

May 28, 2015: OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab During Conference Call on Tuesday, June 2, 2015

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by AbbVie Inc, H2 2016

Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016

Pipeline by PharmAbcine, Inc., H2 2016

Pipeline by Sevion Therapeutics, Inc., H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016 37List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • PharmAbcine, Inc.
  • Sevion Therapeutics, Inc.
  • MORE
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Delta like ligand 4 (DLL4) is a member of the Delta family of Notch ligands. Delta like ligand 4 is a protein encoded by DLL4 gene. High selective expression pattern of DLL4 is found within the vascular endothelium. DLL4 is upregulated by hypoxia and vascular endothelial growth factor-A (VEGF-A). DLL4 plays a fundamental role in pathological angiogenesis, as blockers of the Dll4 / Notch pathway result in decreased tumor growth.

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively.

Our latest report Delta Like Protein 4 – Pipeline Review, H2 2016, outlays comprehensive information on the Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
OncoMed Pharmaceuticals, Inc.
PharmAbcine, Inc.
Sevion Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll